F8 and hemophilia: In the dose- and frequency-escalated Canadian Hemophilia Primary Prophylaxis Study, 54% (25/46) of pediatric participants (initially aged 1.0-2.5 years with normal joints) developed synovial hypertrophy and hemosiderin deposition after 9.6 years of FVIII prophylaxis [34].